Ann: Bod formalises Agreement with Linnea, page-2

Company is a massive sleeper. Revenues should be building, agreement formalised, exploring pathways to market and should have plenty of news to come - nioskin angle sounds interesting.

Bod is currently actively evaluating a number of paths to market, including therapeutic products for treating Multiple Sclerosis, Epilepsy and Chemotherapy‐induced Nausea and Vomiting.

Additionally, under the agreement Bod will develop a range of premium cosmetics and topical skin care products based on Linnea’s NioSkin™ range of active cosmetic ingredients, which incorporate the ground‐breaking Niosomal Delivery system to improve the skin penetration of natural ingredients.

DYOR, but worth keeping an eye on IMO.